BioSpectrum Asia Magazine - February 2022Add to Favorites

BioSpectrum Asia Magazine - February 2022Add to Favorites

Go Unlimited with Magzter GOLD

Read BioSpectrum Asia along with 8,500+ other magazines & newspapers with just one subscription  View catalog

1 Month $9.99

1 Year$99.99 $49.99

$4/month

Save 50% Hurry, Offer Ends in 3 Days
(OR)

Subscribe only to BioSpectrum Asia

1 Year$11.88 $7.99

Save 33% Easter Sale!. ends on April 1, 2024

Buy this issue $0.99

Gift BioSpectrum Asia

7-Day No Questions Asked Refund7-Day No Questions
Asked Refund Policy

 ⓘ

Digital Subscription.Instant Access.

Digital Subscription
Instant Access

Verified Secure Payment

Verified Secure
Payment

In this issue

BOOM OR BUST FOR ASIAN HEALTHCARE
Asia Pacific (APAC) is leaping with novel innovations while connecting the APAC market with global trends. Life sciences sector remains an attractive industry for investment from both strategic players and financial investors. The accelerated R&D activities amidst the pandemic attracted both outward direct investment (ODI) and foreign direct investment (FDI) in potential bio-pharma sectors at an estimated size of $40.25 billion in 2021. The surge in the pandemic is burgeoning consumer demand for innovative and potential healthcare products with the emerging digital health tech market. Thus, it’s essential to statistically analyse the perspective of the investment attractiveness in the APAC economy and translate it into a quantitative score to benchmark the performance of innovation and investments. Let’s gather some industry perspective on policy strengths and challenges in the markets for different stakeholders.

US Highlights Covid-19 Neurological Symptoms

SARS-CoV-2 was initially identified as a respiratory virus, but it can affect the entire body, including the nervous system.

US Highlights Covid-19 Neurological Symptoms

1 min

Boom Or Bust For Asian Healthcare?

Asia Pacific (APAC) is leaping with novel innovations while connecting the APAC market with global trends. Life sciences sector remains an attractive industry for investment from both strategic players and financial investors. The accelerated R&D activities amidst the pandemic attracted both outward direct investment (ODI) and foreign direct investment (FDI) in potential bio-pharma sectors at an estimated size of $40.25 billion in 2021. The surge in the pandemic is burgeoning consumer demand for innovative and potential healthcare products with the emerging digital health tech market. Thus, it’s essential to statistically analyse the perspective of the investment attractiveness in the APAC economy and translate it into a quantitative score to benchmark the performance of innovation and investments. Let’s gather some industry perspective on policy strengths and challenges in the markets for different stakeholders.

Boom Or Bust For Asian Healthcare?

10+ mins

‘Click M' For Mental Health

Mental health and wellbeing has become a major cause for concern, especially due to the pandemic-induced psychological traumas, stemming from spending long hours in the confines of one’s home, minimal to zero social interaction, inability to meet and greet friends and family, as before and financial insecurity. Little wonder that the mental health space turned out to be ‘the hot’ sector in 2021, with funding more than doubling globally, climbing from $2.3 billion to $5.5 billion. As app-based mental health solutions are becoming a rage in APAC, we take a quick look at a few promising players.

‘Click M' For Mental Health

10 mins

How IP Nitty-gritties Hinder Universal Immunisation

Since the COVID-19 immunisation started almost a year ago in January 2021, 60.2 per cent of the world population has received at least one dose of a COVID-19 vaccine and only 9.4 per cent of people in low-income countries have received at least one dose (source: our world in data). While there are many challenges to do so, the repeated argument being ‘pharma companies should forego Intellectual Property (IP) to expedite universal immunisation’. Should pharma companies waive IP during the pandemic? Will this ensure universal immunisation and equal distribution of therapies? Let’s find out.

How IP Nitty-gritties Hinder Universal Immunisation

5 mins

Read all stories from BioSpectrum Asia

BioSpectrum Asia Magazine Description:

PublisherMM Activ Sci-Tech Communication

CategoryBusiness

LanguageEnglish

FrequencyMonthly

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.

  • cancel anytimeCancel Anytime [ No Commitments ]
  • digital onlyDigital Only
MAGZTER IN THE PRESS:View All